Akebia Therapeutics (AKBA) Cost of Revenue (2018 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Cost of Revenue of $12.3 million for Q1 2026, up 61.18% year-over-year from $7.6 million in Q1 2025, and down 1.95% quarter-over-quarter from $12.5 million in Q4 2025.
Akebia Therapeutics (AKBA) Cost of Revenue (2018 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Cost of Revenue for 9 consecutive years, with $12.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue rose 61.18% year-over-year to $12.3 million; the TTM figure through Mar 2026 stood at $44.1 million (up 7.16% YoY), while the FY2025 annual figure was $39.5 million, up 45.43% from the prior year.
- Cost of Revenue slipped to $12.3 million in Q1 2026 per AKBA's latest filing, from $12.5 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $38.3 million in Q3 2022 and bottomed at $5.1 million in Q3 2024.
- Historically, Cost of Revenue has averaged $15.1 million across 5 years, with a median of $12.3 million in 2026.
- Annual changes were most pronounced in 2022 — Cost of Revenue soared 452.16% — and 2024, when it sank 71.4%.
- Akebia Therapeutics' Cost of Revenue stood at $23.6 million in 2022, then plunged by 59.09% to $9.7 million in 2023, then gained by 17.61% to $11.4 million in 2024, then rose by 10.39% to $12.5 million in 2025, then decreased by 1.95% to $12.3 million in 2026.
- Business Quant data shows AKBA's Cost of Revenue at $12.3 million in Q1 2026, $12.5 million in Q4 2025, and $9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 10.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.42 Mn |
| Jun 30, 2026 | 10.42 Mn |
| Mar 31, 2026 | 12.29 Mn |
| Mar 31, 2026 | 12.29 Mn |
| Dec 31, 2025 | 12.54 Mn |
| Dec 31, 2025 | 12.54 Mn |
| Sep 30, 2025 | 9.38 Mn |
| Sep 30, 2025 | 9.38 Mn |
| Jun 30, 2025 | 9.92 Mn |
| Jun 30, 2025 | 9.92 Mn |
| Mar 31, 2025 | 7.63 Mn |
| Mar 31, 2025 | 7.63 Mn |
| Dec 31, 2024 | 11.36 Mn |
| Dec 31, 2024 | 11.36 Mn |
| Sep 30, 2024 | 5.15 Mn |
| Sep 30, 2024 | 5.15 Mn |
| Jun 30, 2024 | 17.05 Mn |
| Jun 30, 2024 | 17.05 Mn |
| Mar 31, 2024 | 11.61 Mn |
| Mar 31, 2024 | 11.61 Mn |